The Duchenne Muscular Dystrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Duchenne Muscular Dystrophy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued products.

GlobalData tracks 198 drugs in development for Duchenne Muscular Dystrophy by 140 companies/universities/institutes. The top development phase for Duchenne Muscular Dystrophy is preclinical with 108 drugs in that stage. The Duchenne Muscular Dystrophy pipeline has 175 drugs in development by companies and 23 by universities/ institutes. Some of the companies in the Duchenne Muscular Dystrophy pipeline products market are: Sarepta Therapeutics, Dyne Therapeutics and Pepgen.

The key targets in the Duchenne Muscular Dystrophy pipeline products market include Dystrophin (DMD), Utrophin (Dystrophin Related Protein 1 or DRP1 or UTRN), and Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1).

The key mechanisms of action in the Duchenne Muscular Dystrophy pipeline product include Dystrophin (DMD) Activator with 79 drugs in Pre-Registration. The Duchenne Muscular Dystrophy pipeline products include 12 routes of administration with the top ROA being Intravenous and 14 key molecule types in the Duchenne Muscular Dystrophy pipeline products market including Small Molecule, and Antisense Oligonucleotide.

Duchenne Muscular Dystrophy overview

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. Risk factors include gender and family history. Treatments include steroid medication, respiratory therapy, and surgery.

For a complete picture of Duchenne Muscular Dystrophy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.